"name","description","uuid:ID","label","id","instanceType","rationale"
"Study Design 1","The main design for the study","40d92a5c-1b80-4876-83a8-3f20275111af","","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
